Tag
USFDA
3 articles
Strides Pharma Receives USFDA Form 483 with 5 Observations
Strides Pharma discloses completion of a routine USFDA cGMP inspection at its Bangalore flagship facility from May 12-20, 2026.
The USFDA issued a Form 483 containing five observations at the conclusi
SPARC FY26 Net Profit Surges to ₹15,521 Crore
SPARC reported a massive FY26 standalone net profit of ₹15,521 crore, a dramatic turnaround from a ₹3,452 crore loss in FY25, driven by a ₹18,400 crore Priority Review Voucher sale.
The company receiv
Bharat Parenterals FY26 Consolidated Loss ₹27.3 Cr
Bharat Parenterals reported consolidated FY26 revenue of ₹345.4 Cr with a PAT loss of ₹27.3 Cr, driven by subsidiary Innoxel's pre-commercial phase.
Innoxel Lifesciences secured USFDA and EU-GMP appro